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ABSTRACT: 
Objectives: To investigate differences in management and outcomes for patients admitted to 
hospital with TIA according to care on a stroke unit (SU) or alternate ward setting up to 180-
days post event. 
Methods: TIA admissions from 40 hospitals participating in the Australian Stroke Clinical 
Registry during 2010-13 were assessed. Propensity score matching was used to assess 
outcomes by treatment group including Cox proportional hazards regression to compare 
survival differences and other appropriate multivariable regression models for outcomes 
including health-related quality of life and readmissions.  
Results: Among 3007 patients with TIA (mean age 73 years, 54% male), 1110 pairs could be 
matched. Compared to management elsewhere in hospitals, management in a SU was 
associated with improved cumulative survival at 180-days post-event (hazard ratio [HR] 0.57, 
95% confidence interval [CI] 0.35 to 0.94; p=0.029), despite not being statistically significant 
at 90-days (HR 0.66, 95% CI 0.33 to 1.31; p=0.237). Overall, there were no differences for 
being discharged on antihypertensive medication or with a care plan; and the 90-180 day self-
reported outcomes between these groups were similar. In subgroup analyses of 461 matched 
pairs treated in hospitals in one Australian state (Queensland), patients treated in a SU were 
more often prescribed aspirin within 48 hours (73% vs 62%, p<0.001) and discharged on 
antithrombotic medications (84% vs 71%, p<0.001) than those not treated in a SU. 
Conclusion: Hospitalised patients with TIA managed in SUs had better survival at 180-days 
than those treated in alternate wards, potentially through better management, but further 
research is needed. 
 
Words: 250  
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Introduction 
Management in a stroke unit (SU) is recommended for patients with acute stroke,1 reducing 
the odds of death or dependency by over 20% compared to alternate wards.2 SU care involves 
management by clinicians with specialist training and expertise in stroke3 who provide 
greater access to evidence-based care including acute interventions and secondary 
prevention.4 In alternate wards, patients are managed by a range of health professionals who 
may not have specific expertise in stroke or transient ischemic attack (TIA). 
 
Data are limited regarding the ideal care pathway for patients with TIA once a decision has 
been made to admit them to hospital.5-8 Recent findings from 15 hospitals contributing to a 
German registry, provided evidence that management in a SU was associated with reduced 
risk of stroke or death at 90-days only in men with TIA.5 In Australia, declining trends in the 
90-day risk of stroke were observed in patients with an incident TIA if managed in hospitals 
with a SU.8 
 
It remains unclear if patients with TIA have any longer-term benefits associated with 
management in an SU. In order to investigate this, we used data obtained prospectively by 
clinicians or directly from patients or outcome assessors from the Australian Stroke Clinical 
Registry (AuSCR).9 We hypothesized that, among patients hospitalised for TIA, management 
in an SU would be associated with (1) fewer deaths within 180 days, and (2) greater 
utilisation of evidence-based processes of care, when compared to management in an 
alternate ward. 
 
Methods 
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Patient population and procedures 
The AuSCR was established in 2009 to routinely monitor processes of care and health 
outcomes between 90 to 180 days after symptom onset on consecutive, hospitalised cases of 
stroke or TIA (see protocol9 and www.auscr.com.au). The AuSCR provides a minimum 
national dataset of process of care indicators that can be used to provide an assessment of 
differences in the quality of care and outcome of patients with TIA. Briefly, the AuSCR 
adheres to the Australian guidelines for best-practice in clinical quality registries.10 The 
current analysis incorporates data from all 40 hospitals that contributed data during the period 
2010 to 2013. 
 
Within the AuSCR, TIA is defined using clinical criteria based on an adaption of the more 
classical epidemiological approach as a definitive or probable diagnosis at the time of 
discharge from hospital that is compatible with a TIA using symptoms of neurological 
deficits (persisting for <24 hours from onset) and/or neuroimaging evidence (no 
abnormalities detected). International classification of disease version 10 primary discharge 
codes are also obtained but were not used to classify patients in this study since coding is 
undertaken by administrative staff and not clinicians within Australia. All clinical staff who 
collect and enter the AuSCR data are provided with standardised training and a data 
dictionary. Random audits of medical records are also undertaken by external auditors to 
verify the quality of the AuSCR data including clinical diagnosis and additional training 
provided, if needed.9  
 
The processes of care collected in the AuSCR by all hospitals include: management on a 
stroke unit; treatment with intravenous tissue plasminogen activator if an ischemic stroke; 
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provision of an antihypertensive agent at discharge; and provision of a discharge care plan 
developed with the patient or family. In hospitals located in one Australian state 
(Queensland), an additional four processes of care have been collected since 2012: mobilised 
during admission; aspirin administration within 48 hours; swallow assessment and formal 
speech pathologist review; and discharged on antithrombotic medications. Missing or 
unknown data were assumed to be negative for processes of care (ranged from 0% to 8%). 
 
The AuSCR protocol incorporates an ‘opt-out’ approach whereby all eligible cases are 
registered unless the patient or family nominates to have their data excluded via simple, cost-
free options (free-call telephone number or postage-paid). This approach ensures that 
selection bias is minimised.11 To date, <3% of participants have opted out of the AuSCR. 
 
Patients who were discharged from the participating hospitals, and who had not refused 
follow-up or ‘opted-out’ of the registry, were followed-up centrally by trained research staff 
between 90 to 180 days after symptom onset. A modified Dillman protocol was used, 
whereby two attempts by post were made prior to an attempt by telephone. Although multiple 
episodes of care are registered in the AuSCR, patients were only followed up after their first 
episode.9 At follow-up, data on health-related quality of life (HRQoL) are collected using the 
EuroQoL-5 dimension-3 level (EQ-5D-3L) instrument.12 Index-based values (‘utilities’) for 
the EQ-5D-3L have been reported using health values derived using Discrete Choice 
Experiment (DCE) methods in Australia.13 A utility score of 0 corresponds to a HRQoL state 
equivalent to death, while a score of 1 represents perfect HRQoL. Patient report of 
subsequent readmission to hospital and stroke is also recorded. 
 
Data linkage  
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Personal identifiers of all registrants in AuSCR were linked to the National Death Index 
(NDI) using probabilistic matching by the Australian Institute of Health and Welfare. For 
these analyses, mortality data in the NDI were used. We also report mortality to 90 days as 
this is common to other studies of TIA.  
 
The socioeconomic status of participants was estimated using the Index of Relative 
Socioeconomic Disadvantage (IRSD) provided by the Australian Bureau of Statistics.14 The 
IRSD is calculated for State Suburb Codes using national census data on people and 
households within those areas, including education, occupation, living conditions and 
income. Greater IRSD scores indicate lesser relative disadvantage.  
 
Ethics 
Appropriate ethics and/or governance approvals were obtained for all participating hospitals 
in AuSCR. Ethical approval was obtained from the Australian Institute of Health and Welfare 
to conduct data linkage to the National Death Index. 
 
Statistical analysis 
Kruskal-Wallis tests and chi2 tests were used to assess differences in patient characteristics. 
Propensity score matching was used to isolate the influence of SU management and improve 
internal validity. A propensity score was calculated for all patients with TIA based on age, 
sex and ability to walk on admission (as a marker of symptom severity/co-morbidity at time 
of admission to hospital).15 Each patient who did not receive treatment in a SU was matched 
to a similar patient with TIA who received treatment in a SU based on this propensity score 
and then processes of care and outcomes were compared.   
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Regression models for the analysis of outcomes using matched pairs were adjusted for age, 
sex, IRSD, ability to walk on admission, in-hospital TIA, history of stroke and transfer from 
another hospital. Outcome data were analysed by individual patient and not by episode. Cox 
proportional hazards regression analysis was conducted to assess rates of death within 90 and 
180 days. Quantile regression analysis was also conducted to investigate differences in 
HRQoL utility scores. Random-effects logistic regression analysis was conducted to 
investigate re-hospitalization, and occurrence of stroke or recurrent TIA. To adjust for patient 
clustering by hospital we used multi-level analyses for logistic regression analyses, but when 
using Cox and quantile regression we adjusted for patient clustering directly. As a sensitivity 
analysis, regression analyses without propensity score matching were also undertaken. Data 
were analysed using StataIC 12.1 (StataCorp 2013). 
 
Results  
Among the 3007 registered episodes of TIA (median age 74, male 54%), 1997 were admitted 
to a SU. Overall, patients with TIA were less often managed in a SU than patients with 
confirmed stroke (66% vs ischemic stroke 83%, p<0.001) indicating that they more often 
received care elsewhere within a hospital. Patients treated in SUs were less disadvantaged, 
less often born in Australia, less often had an in-hospital event and were more often 
discharged home than those not treated in SUs (Table 1). In the subset of patients with TIA 
from Queensland hospitals, those treated in a SU were more often treated with aspirin within 
48 hours of admission (73% vs 62%, p<0.001) and were more often discharged on 
antithrombotic medication (84% vs 71%, p<0.001) compared to those treated on an alternate 
ward (Table 2). 
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Few patients with TIA died in hospital (n=5). Using the propensity score matched sample, the 
number of deaths at 90 and 180 days after admission were similarly low for patients with TIA 
who were and were not admitted to a SU (90-days: no SU care n=21 [2.2%] and SU care 
n=17 [1.8%]; 180-days: no SU care n=49 [5.2%] and SU care n=30 [3.2%]). In Cox 
proportional hazards regression analysis, there were no differences in the hazard of death at 
90 days after admission for TIA between those who were and were not admitted to a SU 
(Table 3 and Figure 1, hazard ratio [HR] 0.66, 95% confidence interval [CI]: 0.33 – 1.31; 
p=0.237). However, patients with TIA who were managed in a SU had a reduced hazard of 
death at 180-days after admission (HR 0.57, 95% CI: 0.35 – 0.94, p=0.029) when compared 
to patients not admitted to a SU. 
 
A greater proportion of patients with TIA treated in a SU completed a follow-up interview 
than those not treated in a SU (SU 59% vs 48%, p<0.001). The median time to follow-up was 
101 days (interquartile range 96 – 107). There was no statistical difference in proportion 
reporting readmission to hospital based on care setting (SU 22% vs non-SU 24%, p=0.432). 
Similarly, there were no detectable differences based on care setting in reports of new strokes 
since admission (8% in both groups, p=0.806). The median EQ-5D utility score was 0.79 for 
patients who were treated in a SU and 0.81 for those who were not treated in a SU. There 
were no detectable differences in these outcomes between groups after adjustment (Table 4). 
 
The results from the propensity score matching methods were robust. Results were similar 
when the full sample of 3007 TIA patients were included in standard logistic regression 
multi-level models (e.g. difference in HRQoL β coefficient 0.03, 95% confidence interval 
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0.00 – 0.05, p=0.051), except that those managed in SUs were more often discharged on 
antihypertensive medications (70% vs 61%, p<0.001). The hazard of death was similar after 
exclusion of TIAs that occurred while in hospital for another condition and when adjusting 
for symptom-onset-to-arrival time (see online supplement).  
 
Discussion 
This is the largest reported study of outcomes after TIA according to the setting of 
management after admission to hospital. Compared to alternate wards, treatment in a SU was 
associated with a 45% reduced cumulative hazard of death at 180 days, but no difference was 
observed at 90 days. Our results were comparable to studies of the benefits of rapid access 
TIA clinics,16-18 since our 90-day survival rates fell within their 95% confidence limits.  
 
Our results may partly be explained by our low event rates. The proportion of patients in our 
study who reported having had a recurrent stroke at 90-180 days follow-up (8%) was less 
than that reported in a systematic review of 18 studies (average ~11% at 90-days, range 0.6% 
to 20.6%),19 but appeared to be greater than those reported from studies on the benefits of 
rapid-access TIA clinics,16-18 including the Australian M3T model.20 It is possible that a 
different case-mix of patients may have contributed to this observed difference in outcome 
since patients seen in rapid-access TIA clinics tended to be younger (by up to 10 years) than 
in our hospitalized sample. Furthermore, the large proportion of patients with TIA in our 
sample who were unable to walk on admission suggests selection bias towards admission of 
those with more severe or persistent symptoms, and potentially greater co-morbidity or 
frailty, both of which may be associated with greater incidence of subsequent events.  
 
13 
 
A small proportion of patients with TIA were discharged to an aged care facility, and this was 
less often observed if they were managed in a SU.4 This is consistent with the findings of 
another study in which patients with stroke receiving care in a SU were more often 
discharged directly to home when compared to those who received care on a general ward. It 
was anticipated that few patients with TIA would be discharged to aged care, but is difficult 
for us to reconcile. This is because the AuSCR does not collect pre-admission residence and 
so we were unable to identify patients who were living in an aged care facility prior to their 
TIA. We observed that patients who were treated in a SU were less often disadvantaged than 
those who were not. However, we found no association between socioeconomic status and 
outcomes. Nevertheless, this may point to a disparity in healthcare delivery, which warrants 
further investigation.  
 
Processes of care that are characteristic of SUs that potentially improve outcomes include 
delivery of more appropriate early secondary prevention, assessment for etiology, early 
management and discharge care planning.4 In this study, important processes of care, such as 
assessment of swallow function and hyper-acute aspirin therapy, differed between those 
treated in a SU compared to those who were not. However, commencement of early 
secondary prevention prior to discharge was mixed. There was no difference in 
antihypertensive medication prescription on discharge between groups overall, but a 
difference was observed in the Queensland subgroup. When compared to patients with TIA 
managed in an alternate ward, patients with TIA who were managed in a SU were more often 
treated with antithrombotic medications, which is a potential explanatory factor for the 
observed difference in survival. However, the use of antithrombotic medication was only 
captured in hospitals in Queensland (58% of total AuSCR hospitals and 45% of all TIA 
episodes in AuSCR) and these patients may not be representative of all patients from hospital 
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using AuSCR. Additionally, it remains unclear what happens in primary care or the 
outpatient setting post discharge, since only hospital discharge medications are captured in 
this study. It is possible that communication with primary care doctors or follow-up care is 
better for patients experiencing TIA who are treated in a SU than those who are not, 
potentially resulting in a longer term survival advantage.  
 
Importantly, there are different models of care for patients with TIA in Australia.21 Due to the 
milder symptoms associated with TIA, hospitals may have policies to admit these cases to 
short stay units, protocol based observation units, or out-patient clinics that provide a similar 
quality at a reduced cost to hospitals than using an admit-all approach.22, 23 Patients with TIA 
who are admitted are likely to have different characteristics to patients with TIA seen in 
outpatient clinics. Several authors have developed algorithms to identify people with TIA 
who are at greatest risk of early stroke to help fast track the patients who require rapid 
investigation or admission to hospital.24, 25 While some groups have demonstrated safe 
management of TIA without admission to hospital, this is still a specialized alternative.20 
Improving availability of specialised stroke care in Australia, and elsewhere, is likely to 
improve the management of patients hospitalized with TIA. Electronic clinical support tools 
to assist non-neurologists in providing appropriate outpatient care to patients with TIA may 
assist in locations where access to specialists is not feasible.26  
 
The strengths of this study include the large sample size from all 40 hospitals participating in 
the AuSCR during the study period (21% of 195 hospitals known to admit people with acute 
stroke and TIA in Australia)27 located in urban and rural locations; and the confirmation of 
death status in all patients using linked data from the National Death Index. In addition, 
appropriate statistical techniques for non-randomised data, including propensity score 
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matching, were used to maximize comparability between patients who were and were not 
managed in a SU. Therefore, the between-group imbalances in variables used to match are 
unlikely to account for these results. The results from this model were consistent with those 
found using standard analytic methods, thereby demonstrating the robustness of our findings.  
 
There are some limitations to our study. In particular, there were limited covariates available 
in the AuSCR minimum dataset to use in the multivariable analyses, thereby raising the 
potential for residual confounding. For example, established prognostic factors such as 
hypertension, diabetes, TIA duration and clinical symptoms were unavailable. One 
complexity that arises with this, or other standard multivariable statistical approaches, is that 
we cannot accurately account for unmeasured confounding factors. For example, the more 
gradual accumulation of deaths in the non-SU group over time may have been due to greater 
pre-admission co-morbidity that we were unable to take into account. However, we have 
adjusted for a prognostic measure of severity of disease validated for stroke when 
investigating outcomes.15 In future work we will be able to expand our registry variables 
through person-level linkage to other health datasets to enable our models to account for 
important pre-stroke co-morbidity.28 
 
Another limitation is that those who were followed up were more often treated in a SU than 
those who were not. This response bias may explain why we did not observe differences in 
self-reported readmissions, recurrent stroke and HRQoL. In addition, because death, recurrent 
stroke and readmissions were relatively few within the follow-up time frame, we were likely 
underpowered to detect a difference in these outcomes at 90-day follow-up. Unfortunately, 
not all patients were able to be followed-up for HRQoL data due to resource constraints. In 
addition, it was also not possible to adjust for the different policies for management used by 
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hospitals to admit patients with TIA because information on this is not collected in the 
AuSCR. Lastly, duration of care in a SU was not recorded and therefore we were unable to 
investigate a dose-response. 
 
Stroke unit management was associated with reduced mortality at 180 days after admission 
for TIA. Given the non-randomised study design, this finding requires confirmation. In 
addition, whether or not the benefit of SU care persists beyond 180 days after admission for 
TIA should be investigated. Furthermore, it will be important to determine the effect of SU 
care on other outcomes in these patients, such as the adherence to secondary prevention 
therapies and the frequency of future stroke and acute myocardial infarction. Linkage of 
AuSCR data to hospital administrative databases will enable better assessments of subsequent 
cardiovascular events in these patients.28 These findings provide evidence which support the 
treatment of TIA in a SU, where admission to hospital is warranted, as this may improve 
longer-term survival outcomes for patients. 
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Table 1. Demographic and clinical characteristics of patients with TIA 
according to management in a Stroke Unit 
 SU Non-SU  
 N=1997 N=1010  
 n (%)* n (%)* p-value 
Median age in years (IQR) 75  (64 – 83) 74  (64 – 83) 0.622 
Male 1082 (54) 545 (54) 0.909 
IRSD 
Quintile 1 (most disadvantaged) 
Quintile 2 
Quintile 3 
Quintile 4 
Quintile 5 (least disadvantaged) 
 
365 (18) 
353 (18) 
345 (17) 
332 (17) 
602 (30) 
 
268 (27) 
226 (22) 
179 (18) 
141 (14) 
196 (19) 
<0.001 
Born in Australia 1318 (66) 710 (70) 0.018 
Transferred from another hospital 183 (9) 80 (8) 0.259 
Able to walk independently on 
admission‡ 1394 (70) 668 (66) 0.041 
Stroke/TIA occurred in hospital 33 (2) 35 (3) 0.002 
Documented history of stroke 500 (25) 248 (25) 0.772 
Median length of stay in days (IQR) 2 (1 – 4) 2 (1 – 4) <0.001† 
Discharge destination 
 
Home 
Rehabilitation 
Aged care 
Other hospital 
Missing 
 
 
1740 (87) 
84 (4) 
74 (4) 
81 (4) 
16 (1) 
 
 
824 (82) 
19 (2) 
58 (6) 
99 (10) 
7 (1) 
<0.001 
Died in hospital 2 (0) 3 (0) 0.207 
TIA: transient ischemic attack, SU: Stroke unit, IRSD: Index of Relative 
Socioeconomic Disadvantage, IQR: interquartile range 
* unless otherwise stated 
† There was a greater proportion of outliers in regard to length of stay in patients 
with TIA managed in alternate wards than those managed in a SU (3% vs 2% 
greater than 45 days) 
‡ as a marker of severity of symptoms on admission as per the Counsel et al 
prognostic model15 
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Table 2. Matched analysis of processes of care between patients with TIA 
managed and not managed in a Stroke Unit  
 SU Non-SU  
 N=1010 N=1010  
 n (%) n (%) p-value 
Discharged on an antihypertensive medication 640 (64) 616 (62) 0.267 
Patients in Queensland hospitals* 291 (64) 237 (52) <0.001 
Discharged to the community with a care plan 383 (42) 410 (46) 0.073 
Patients in Queensland hospitals† 145 (37) 200 (51) <0.001 
    
Queensland-only processes of care‡    
Mobilised during admission 420 (91) 388 (84) 0.001 
Swallow assessment 357 (77) 224 (49) <0.001 
Aspirin within 48 hours 337 (73) 285 (62) <0.001 
Discharged on antithrombotic medication§ 375 (84) 319 (71) <0.001 
TIA: transient ischemic attack, SU: Stroke Unit, IQR: interquartile range  
* 457 matched pairs of patients discharged 
† 390 matched pairs of patients discharged to the community  
‡ Variables collected in Queensland from 2012 onwards. In Queensland, there were 
461 matched pairs  
§ 449 matched pairs of patients who were discharged 
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Table 3. Survival analysis of patients with TIA based on treatment in Stroke Units 
 Death to 90 days  Death to 180 days 
N=1890  HR (95% CI) p-value  HR (95% CI) p-value 
Treated on a Stroke Unit 
 No 
 Yes 
 
1.00 
0.66 (0.33 – 1.31) 
 
– 
0.237 
 
 
1.00 
0.57 (0.35 – 0.94) 
 
– 
0.029 
Age* 
 <65 
 65-74 
 75-84 
 >85 
 
1.00 
2.49 (0.61 – 10.13) 
3.31 (0.89 – 12.30) 
6.94 (1.93 – 24.98) 
 
– 
0.202 
0.073 
0.003 
 
 
1.00 
2.04 (0.82 – 5.04) 
3.02 (1.32 – 6.95) 
6.47 (2.87 – 14.56) 
 
– 
0.123 
0.009 
<0.001 
Sex* 
 Male 
 Female 
 
1.00 
0.95 (0.49 – 1.82) 
 
– 
0.874 
 
 
1.00 
1.02 (0.65 – 1.61) 
 
– 
0.922 
IRSD quintiles 
 1 (most disadvantaged) 
 2 
 3 
 4 
 5 (least disadvantaged) 
 
1.00 
1.11 (0.43 – 2.82) 
0.52 (0.14 – 1.94) 
0.81 (0.27 – 2.47) 
1.16 (0.48 – 2.79) 
 
– 
0.834 
0.331 
0.717 
0.737 
 
 
1.00 
0.61 (0.28 – 1.32) 
1.13 (0.56 – 2.30) 
0.86 (0.40 – 1.84) 
1.25 (0.68 – 2.30) 
 
– 
0.207 
0.725 
0.703 
0.471 
Ability to walk on admission* 
 No 
 Yes 
 
1.00 
0.30 (0.13 – 0.70) 
 
– 
0.006 
 
 
1.00 
0.50 (0.30 – 0.86) 
 
– 
0.011 
In hospital TIA 
 No 
 Yes 
 
1.00 
4.26 (1.12 – 16.20) 
 
– 
0.029 
 
 
1.00 
3.02 (1.10 – 8.26) 
 
– 
0.032 
Transfer from another hospital 
 No 
 Yes 
 
1.00 
0.32 (0.06 – 1.63) 
 
– 
0.171 
 
 
1.00 
0.28 (0.08 – 1.00) 
 
– 
0.049 
Documented history of stroke 
 No 
 Yes 
 
1.00 
1.07 (0.53 – 2.18) 
 
– 
0.845 
 
 
1.00 
1.45 (0.91 – 2.33) 
 
– 
0.119 
949 matched pairs, eight patients with missing data not included TIA: transient ischemic attack, HR: 
hazard ratio, CI: confidence interval, IRSD: Index of Relative Socioeconomic Disadvantage  
There were no differences to the model when age was included as a continuous variable. 
*Used in propensity score matching procedure as a marker of severity of symptoms on admission 
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Figure 1: Cumulative hazard of death to 180 days after transient ischemic attack 
according to management in a Stroke Unit 
 
Figure 1 legend: 
N=1890 (945 matched pairs) 
Adjusted for age, sex, place of birth, socioeconomic status, ability to walk on admission, in-
hospital transient ischemic attack, history of stroke and transfer from another hospital using a 
matched 1:1 cohort based on propensity score methods. 
Cumulative hazard is the number of events that would be expected for each individual in a 
group at a given time if the event were a repeated process. 
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Table 4. Health related quality of life and self-reported adverse events for 
patients with TIA according to treatment in a Stroke Unit or alternate ward 
 OR* (95% CI) p-value 
Rehospitalisation 0.98 (0.64 – 1.49) 0.924 
Recurrent stroke/TIA 1.18 (0.61 – 2.28) 0.624 
   
EQ-5D-3L DCE method (β coefficient and 95% CI) 0.02 (-0.02 – 0.06) 0.392 
OR: odds ratio unless otherwise stated, CI: confidence interval, TIA: transient 
ischemic attack, EQ-5D-3L: EuroQoL -5 dimension-3 level instrument12, DCE: 
discrete choice experiment utilities determined by Viney et al13 
N=914 (457 matched pairs) in analyses of rehospitalisation and recurrent stroke/TIA, 
N=888 (444 matched pairs) in analysis of EQ-5D-3L DCE 
Outcomes at 90 to 180 days 
Adjusted for age, sex, place of birth, socioeconomic status, ability to walk on 
admission, in-hospital TIA, history of stroke and transfer from another hospital using 
a matched 1:1 cohort based on propensity score methods. 
*treated in a Stroke Unit (SU) vs not treated in a SU (reference category). 
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Supplemental tables 
Table e-1. Survival analysis of patients with TIA based on treatment on a SU with additional 
adjustment for time from onset to arrival 
 Death to 90 days  Death to 180 days 
N=1628  
 HR (95% CI) p-value  HR (95% CI) p-value 
Treated on a Stroke Unit 
 No 
 Yes 
 
1.00 
0.74 (0.33 – 1.65) 
 
– 
0.457 
 
 
1.00 
0.53 (0.30 – 0.94) 
 
– 
0.030 
Age* 
 <65 
 65-74 
 75-84 
 >85 
 
1.00 
2.07 (0.52 – 8.31) 
1.88 (0.46 – 7.67) 
5.21 (1.41 – 19.29) 
 
– 
0.304 
0.378 
0.013 
 
 
1.00 
2.11 (0.79 – 5.64) 
2.45 (0.94 – 6.39) 
6.86 (2.75 – 17.11) 
 
– 
0.135 
0.068 
<0.001 
Sex* 
 Male 
 Female 
 
1.00 
1.56 (0.70 – 3.47) 
 
– 
0.279 
 
 
1.00 
1.41 (0.84 – 2.38) 
 
– 
0.196 
IRSD quintiles 
 1 (most disadvantaged) 
 2 
 3 
 4 
 5 (least disadvantaged) 
 
1.00 
0.79 (0.27 – 2.28) 
0.41 (0.09 – 1.95) 
0.51 (0.13 – 1.97) 
1.03 (0.39 – 2.74) 
 
– 
0.661 
0.262 
0.331 
0.952 
 
 
1.00 
0.46 (0.19 – 1.11) 
1.17 (0.55 – 2.49) 
0.50 (0.19 – 1.28) 
1.15 (0.59 – 2.23) 
 
– 
0.085 
0.692 
0.147 
0.682 
Ability to walk on admission* 
 No 
 Yes 
 
1.00 
0.44 (0.18 – 1.11) 
 
– 
0.082 
 
 
1.00 
0.62 (0.35 – 1.11) 
 
– 
0.109 
Transfer from another hospital 
 No 
 Yes 
 
1.00 
0.82 (0.10 – 6.43) 
 
– 
0.848 
 
 
1.00 
0.39 (0.05 – 2.91) 
 
– 
0.359 
Documented history of stroke 
 No 
 Yes 
 
1.00 
1.19 (0.52 – 2.72) 
 
– 
0.684 
 
 
1.00 
1.82 (1.08 – 3.06) 
 
– 
0.025 
Time from onset to arrival (hours) 0.96 (0.89 – 1.02)  0.192  0.99 (0.97 – 1.01) 0.399 
816 matched pairs, four patients with missing data not included 
TIA: transient ischemic attack, HR: hazard ratio, CI: confidence interval, IRSD: Index of Relative 
Socioeconomic Disadvantage 
There were no differences to the model when age was included as a continuous variable. 
*Used in propensity score matching procedure as a marker of severity of symptoms on admission 
 
  
Table e-2. Survival analysis of patients with TIA based on treatment on a SU with exclusion of 
TIAs that occurred while in hospital for another condition 
 Death to 90 days  Death to 180 days 
N=1827  
 HR (95% CI) p-value  HR (95% CI) p-value 
Treated on a Stroke Unit 
 No 
 Yes 
 
1.00 
0.87 (0.42 – 1.78) 
 
– 
0.695 
 
 
1.00 
0.65 (0.39 – 1.10) 
 
– 
0.028 
Age* 
 <65 
 65-74 
 75-84 
 >85 
 
1.00 
3.64 (0.91 – 14.52) 
3.57 (0.94 – 13.58) 
7.50 (2.03 – 27.80) 
 
– 
0.067 
0.062 
0.003 
 
 
1.00 
3.03 (1.18 – 7.76) 
3.62 (1.49 – 8.79) 
8.37 (3.52 – 19.92) 
 
– 
0.021 
0.005 
<0.001 
Sex* 
 Male 
 Female 
 
1.00 
1.08 (0.55 – 2.11) 
 
– 
0.828 
 
 
1.00 
1.04 (0.66 – 1.65) 
 
– 
0.859 
IRSD quintiles 
 1 (most disadvantaged) 
 2 
 3 
 4 
 5 (least disadvantaged) 
 
1.00 
1.30 (0.51 – 3.31) 
0.57 (0.15 – 2.15) 
0.85 (0.27 – 2.62) 
1.07 (0.41 – 2.76) 
 
– 
0.582 
0.405 
0.773 
0.894 
 
 
1.00 
0.69 (0.32 – 1.48) 
1.23 (0.60 – 2.50) 
0.72 (0.32 – 1.64) 
1.22 (0.65 – 2.31) 
 
– 
0.340 
0.576 
0.437 
0.532 
Ability to walk on admission* 
 No 
 Yes 
 
1.00 
0.39 (0.16 – 0.95) 
 
– 
0.038 
 
 
1.00 
0.59 (0.34 – 1.04) 
 
– 
0.066 
Transfer from another hospital 
 No 
 Yes 
 
1.00 
0.39 (0.05 – 2.95) 
 
– 
0.364 
 
 
1.00 
0.45 (0.11 – 1.88) 
 
– 
0.274 
Documented history of stroke 
 No 
 Yes 
 
1.00 
1.21 (0.59 – 2.48) 
 
– 
0.598 
 
 
1.00 
1.63 (1.01 – 2.63) 
 
– 
0.044 
918 matched pairs, nine patients with missing data not included 
TIA: transient ischemic attack, HR: hazard ratio, CI: confidence interval, IRSD: Index of Relative 
Socioeconomic Disadvantage 
There were no differences to the model when age was included as a continuous variable. 
*Used in propensity score matching procedure as a marker of severity of symptoms on admission 
 
